Your browser doesn't support javascript.
loading
N-(3-hydroxymethyl-ß-carboline-1-yl-ethyl- 2-yl)-l-Phe: development toward a nanoscaled antitumor drug capable of treating complicated thrombosis and inflammation.
Wu, Jianhui; Zhao, Ming; Wang, Yuji; Wang, Yaonan; Zhu, Haimei; Zhao, Shurui; Gui, Lin; Zhang, Xiaoyi; Peng, Shiqi.
  • Wu J; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Zhao M; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China;
  • Wang Y; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Wang Y; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Zhu H; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Zhao S; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Gui L; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Zhang X; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
  • Peng S; Beijing Area Major Laboratory of Peptide and Small Molecular Drugs; Engineering Research Center of Endogenous Prophylactic, Ministry of Education of China; Beijing Laboratory of Biomedical Materials; College of Pharmaceutical Sciences, Capital Medical University, Beijing, People's Republic of China.
Drug Des Devel Ther ; 11: 225-239, 2017.
Article en En | MEDLINE | ID: mdl-28176928
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fenilalanina / Trombosis / Carbolinas / Nanopartículas / Inflamación / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Fenilalanina / Trombosis / Carbolinas / Nanopartículas / Inflamación / Antineoplásicos Límite: Animals / Humans / Male Idioma: En Año: 2017 Tipo del documento: Article